A study of advanced melanoma patients found that those with sufficient vitamin D levels had significantly better responses to anti-PD-1 immunotherapy, including higher tumor response rates and longer survival without disease progression. Patients with adequate vitamin D had a median progression-free survival of 11.25 months, more than double the 5.75 months seen in vitamin D-deficient patients and showed a trend toward longer overall survival. It helps optimize the immune environment for cancer treatment, potentially by enhancing the activity of cancer-killing T-cells and controlling inflammation that can hinder an effective immune response. While the body’s natural production of vitamin D via sunlight is efficient,…

Newswire

Features

The Latest